A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

PFS is defined as the time from randomization to the date of progression or death, whichever occurs first.

PFS is defined as the time from randomization to the date of progression or death, whichever occurs first.

The rate of undetectable minimal residual disease (uMRD4) in peripheral blood based on next-generation sequencing (NGS)

Complete Response Rate (CRR) is defined as the percentage of participants that achieve a best response of complete response (CR) or complete response with incomplete hematopoietic recovery (CRi)

Overall survival (OS) is defined as the time from the date of randomization to the date of death

PFS is defined as the time from randomization to the date of progression or death, whichever occurs first.

CRR is defined as the percentage of participants that achieve a best response of CR or CRi

OS is defined as the time from the date of randomization to the date of death

The rate of uMRD4 in peripheral blood based on NGS

PFS is defined as the time from randomization to the date of progression or death, whichever occurs first.

CRR is defined as the percentage of participants that achieve a best response of CR or CRi

OS is defined as the time from the date of randomization to the date of death

The rate of uMRD4 in peripheral blood based on NGS

The rate of uMRD4 in peripheral blood based on NGS

CRR is defined as the percentage of participants that achieve a best response of CR or CRi

PFS is defined as the time from randomization to the date of progression or death, whichever occurs first.

PFS is defined as the time from randomization to the date of progression or death, whichever occurs first.

CRR is defined as the percentage of participants that achieve a best response of CR or CRi

OS is defined as the time from the date of randomization to the date of death

The rate of uMRD4 in peripheral blood based on NGS

ORR is defined as the percentage of participants that achieve a best response of partial response (PR) or better

DOR is defined as the time from the date that response criteria were first met to the date of first documentation of disease progression or death, whichever occurs first

TTR is defined as the time from the date of randomization to the date response criteria were first met

TTNT is defined as the time from the date of randomization to the date of next anti-CLL/SLL treatment

The rate of uMRD4 in peripheral blood based on NGS

The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 =Not at all (best) to 4 =Very Much (worst) and 2 questions answered on a 7-point scale where 1 =Very poor (worst) to 7 =Excellent (best). Higher scores in global health status (GHS) and functional scales indicate better health-related quality of life (HRQoL).

The EORTC QLQ-CLL17 is the CLL module of QLQ-C30 consisting of 17 items and comprising 3 scales: symptom burden due to disease and/or treatment (6 items), physical condition/fatigue (4 items), and worries/fears about health and functioning (7 items) Items are rated using a 4-point response scale ("not at all," "a little," "quite a bit," and "very much") and the recall period for all items is the past 7 days. Lower scores indicate better HRQoL.

Number of participants with TEAEs, including laboratory values, vital signs, and physical examination findings, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0.